Oncologists and pathologists are increasingly utilizing information on genomic alterations in tumors to help guide patient care and treatment. Personalis, Inc., a genomic sequencing and interpretation company, has developed a tumor-profiling test that provides clinicians with accurate and comprehensive analysis and clinical reporting of 181 genes to guide treatment decisions.
- Understand the current industry challenges with regard to NGS technology and tumor profiling for clinical care.
- Appreciate how the use of Personalis’ accuracy and content enhanced (ACE) sequencing platform with DNA & RNA analysis improves precision and reporting in solid tumor testing.
- Recognize, through case studies, some of the more common molecular changes identified that may assist in therapeutic management.